Editas Medicine is a clinical-stage gene editing company using CRISPR technology to develop treatments for serious genetic diseases. Editas has no approved products and generates revenue entirely from licensing its CRISPR intellectual property. Its lead program, EDIT-401, is a one-time in vivo CRISPR therapy targeting hyperlipidemia by editing the LDL receptor gene to boost LDL-C clearance from the bloodstream. In preclinical non-human primate studies, a single dose reduced LDL-C by roughly 90%. Editas is targeting an IND submission by mid-2026 and first-in-human data by year-end 2026. Beyond EDIT-401, Editas is developing an in vivo program to treat sickle cell disease and beta thalassemia by editing hematopoietic stem cells to boost fetal hemoglobin production, though this program is secondary to EDIT-401. Editas holds exclusive licenses from the Broad Institute and Harvard covering foundational Cas9 and Cas12a patent estates, which it argues gives it the ability to target over 95% of the human genome. Editas out-licenses this IP to generate non-dilutive income: it has a collaboration with Bristol Myers Squibb for T cell cancer therapies and a Cas9 license with Vertex for use in CASGEVY, the approved sickle cell gene editing therapy. Editas is pre-revenue on products, burns cash, and funds operations through licensing income and capital raises.